Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 11 EP applications Holger Petersen has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after July 16, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP14776739

BLISTER TRACK INHALER DEVICE HAVING A SEPARATE END PATH AND METHODS OF USE THEREOF

IPC classification:
A61M 15/00
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14821857

DRUG DELIVERY SYSTEMS

IPC classification:
A61K 47/36, A61K 47/26, A61K 9/06
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP14824115

PHARMACEUTICAL COMBINATIONS

IPC classification:
A61P 35/00, A61K 31/519, A61K 31/505, A61K 31/4188
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15199469

NOVEL PHARMACEUTICAL COMPOSITION

IPC classification:
A61K 31/4152, A61P 7/06, A61K 47/34, A61K 9/54, A61K 9/14
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP16183711

METHODS OF ADMINISTRATION OF THROMBOPOIETIN AGONIST COMPOUNDS

IPC classification:
A01N 43/56
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
Request for examination was made
EP15733926

INTERMITTENT DOSING OF MDM2 INHIBITOR

IPC classification:
A61P 35/00, A61K 31/496, A61K 31/472, A61K 31/47, A61K 31/4439, A61K 31/4418, A61K 31/4178, A61K 31/404, A61K 31/402
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15738484

PHARMACEUTICAL DOSAGE FORMS

IPC classification:
A61K 31/45, A61K 9/20
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
EXAMINATION REQUESTED
EP15825885

COMBINATION THERAPIES

IPC classification:
A61K 31/00, A61P 35/00, C07K 16/28
Applicant:
Novartis AG
Agent:
Glyn John Truscott, Elkington and Fife LLP
Agent:
Holger Petersen, Novartis Pharma AG
Status:
Request for examination was made
EP16702814

PROCESS FOR THE PRODUCTION OF CONDENSED IMIDAZOLO DERIVATIVES

IPC classification:
A61P 5/46, A61K 31/4184, C07D 233/54
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
Request for examination was made
EP16758275

GDF-15 AS A HAEMATOLOGICAL TOXICITY BIOMARKER

IPC classification:
G01N 33/52, A61K 31/496, G01N 33/50
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
Request for examination was made
EP16760803

MDM2 INHIBITORS AND COMBINATIONS THEREOF

IPC classification:
A61P 35/00, A61K 31/5375, A61K 31/519, A61K 31/506, A61K 31/496
Applicant:
Novartis AG
Agent:
Holger Petersen, Novartis Pharma AG
Status:
Request for examination was made

Please Sign in to use this feature